Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Represents Underwriters in Nabriva Therapeutics IPO

September 30, 2015

NEW YORK - Covington advised the underwriters in the $106.1 million initial public offering by Austrian-based Nabriva Therapeutics AG of 10,350,000 million American Depositary Shares, representing 1,035,000 shares of Nabriva’s common stock. This was the first U.S. initial public offering by an Austrian company. The ADSs are now listed on the NASDAQ Global Market under the ticker “NBRV.”

Based in Vienna, Nabriva is a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. Nabriva is developing its lead product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans.

The Covington corporate team was led by partners Eric Blanchard and Brian Rosenzweig and included associates Matt Gehl, Mark Johnson, Megan Woodford and Laura Torre.  Assistance was provided by special counsel Marianne McKeon (FINRA); senior counsel Peter Safir (U.S. regulatory), partner Robin Blaney and associate Charlotte Ryckman (E.U. regulatory); special counsel Rick Longton and associate Allen Kathir (IP), partner Daniel Luchsinger and associate Adele Faure (tax) and Gus Caywood (legal opinion).


Share this article: